oHSV2-PD-L1/CD3-BsAb

· Binhui Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for oHSV2-PD-L1/CD3-BsAb, covering 2025-11-19 to 2025-11-19. Get the full timeline:

Most recent: Clinical Trial Update: oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection [Phase 1]